NEKTAR THERAPEUTICS

(c) Director and Section 16 Officer Trading Arrangements and Policies

Howard W. Robin, our President and Chief Executive Officer, entered into a pre-arranged stock trading plan on May 22, 2025. Mr. Robin’s trading plan provides for the sale of up to an aggregate 19,998 (on a post-reverse split basis) shares of the Company’s common stock (comprised of previously vested restricted stock units and exercised stock options), which plan has a duration of the earlier of May 19, 2026 or such date upon which all transactions are completed or expire without execution. This trading plan is intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act.

Jonathan Zalevsky, Ph.D., our Chief Research and Development Officer, entered into a pre-arranged stock trading plan on May 16, 2025. Dr. Zalevsky’s trading plan provides for the sale of up to an aggregate 6,073 (on a post-reverse split basis) shares of the Company’s common stock (comprised of previously vested restricted stock units), which plan has a duration of the earlier of May 8, 2026, or such date upon which all transactions are completed or expire without execution. This trading plan is intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act.

In the fiscal quarter ended June 30, 2025, no other directors or Section 16 officers of the Company adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408 of Regulation S-K.